Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152971 · ClinicalTrials.gov registry record · Phase 3
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,615
- Enrollment target
NCT00152971 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,615 participants.
The verdict
NCT00152971, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,615 participants
- Enrollment target
Study Summary
To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared to enoxaparin 30 mg twice a day subcutaneous, in prevention of venous thromboembolism in patients with primary elective total knee replacement surgery
Interventions
- DRUG Enoxaparin
- DRUG Dabigatran Dose 1 - day 2 to completion
- DRUG Dabigatran Dose 1 - day 1
- DRUG Dabigatran Dose 2 - day 2 to completion
- DRUG Dabigatran Dose 2 - day 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,615 participants |
| Start Date | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00152971
The ClinicalTrials.gov registry entry for NCT00152971 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,615 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Enoxaparin is the first listed.
NCT00152971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00152971 about?
NCT00152971 is a clinical study titled "Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement". To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared to enoxaparin 30 mg twice a day subcutaneous, in prevention of venous ...
What is the current status of trial NCT00152971?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,615 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00152971?
The interventions under investigation include: Enoxaparin (DRUG), Dabigatran Dose 1 - day 2 to completion (DRUG), Dabigatran Dose 1 - day 1 (DRUG), Dabigatran Dose 2 - day 2 to completion (DRUG), Dabigatran Dose 2 - day 1 (DRUG).
Who is sponsoring clinical trial NCT00152971?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.